CFM
CRBU icon

Catalyst Funds Management’s Caribou Biosciences CRBU Stock Holding History

Catalyst Funds Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,200
Closed -$61.2K – 709
2026
Q1 		$61.2K Buy
+32,200
New +$55.3K 0.01% 528
2025
Q4 		– Sell
-88,300
Closed -$206K – 388
2025
Q3 		$206K Buy
88,300
+49,600
+128% +$93.6K 0.03% 418
2025
Q2 		$48.8K Buy
+38,700
New +$38.1K 0.01% 375
2024
Q4 		– Sell
-7,800
Closed -$15.3K – 544
2024
Q3 		$15.3K Hold
7,800
– – ﹤0.01% 1125
2024
Q2 		$12.8K Buy
+7,800
New +$24.9K ﹤0.01% 838

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Catalyst Funds Management's CRBU Position: Q2 2026 in Review

Catalyst Funds Management sold out of Caribou Biosciences (CRBU) in Q2 2026, closing a stake of 32,200 shares — an estimated $61.2K sold.

Catalyst Funds Management first reported a position in CRBU in Q2 2024 and held it in 5 quarters. The position peaked at $206K in Q3 2025. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Catalyst Funds Management reported no remaining Caribou Biosciences position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 32,200 Caribou Biosciences shares in Q2 2026, an estimated $61.2K.
  • Catalyst Funds Management first reported a position in Caribou Biosciences in Q2 2024 and held it in 5 quarters.
  • Catalyst Funds Management's Caribou Biosciences position peaked at $206K in Q3 2025.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.